VR Logo

Delcath Systems Inc. (DCTH) download report


Healthcare | Medical Devices & Equipment

Delcath Systems Inc. (DCTH) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe.

IPO Date: 29-May-2018

CEO & Director: Mr. Gerard J. Michel MBA, MS

Chief Operating Officer: Mr. John Purpura M.S.

Listing: NASDAQ: DCTH

Country: United States

Headquarters: New York, NY

Website: https://www.delcath.com

Key Facts

Market cap: $37.49 Mln

Revenue (TTM): $3.55 Mln

Earnings (TTM): $-27.11 Mln

Cash: $16.34 Mln

Total Debt: $16.35 Mln

Insider's Holding: 2.64%

Liquidity: Low

52 Week range: $3.49 - 11.95

Shares outstanding: 7,906,730

10 Years Aggregate:

  • CFO: $-229.59 Mln
  • EBITDA: $-217.88 Mln
  • Net Profit: $-255.27 Mln

Stock Performance

Time Period Delcath Systems (DCTH) S&P BSE Sensex* S&P Small-Cap 600*
YTD-43.951.03-12.41
1 month8.058.637.33
3 months-26.997.331.57
1 Year-57.628.43-9.48
3 Years-60.4117.069.22
5 Years-41.6812.777.59
10 Years-42.8512.8310.53
As on 09-Aug-2022 *As on 08-Aug-2022
Year Delcath Systems (DCTH) S&P Small-Cap 600 S&P BSE Sensex
2021-56.7525.2721.99
2020-15.679.5715.75
2019-89.1620.8614.38
2018202.61-9.705.87
2017-90.0011.7327.91
201684.0024.741.95
2015-58.68-3.36-5.03